Antimicrobial Resistance in Rhodococcus equi and the Promise of Synergistic Therapies
Authors:
- Farzaneh JavadimarandFJFarzaneh Javadimarand
- Pablo CastañeraPCPablo Castañera
- Blanca Lorente-TorresBlanca Lorente-Torres
- Negar MortazaviNMNegar Mortazavi
- Jesús Llano-VerdejaJLJesús Llano-Verdeja
- Sergio Fernández-MartínezSFSergio Fernández-Martínez
- Helena Á. FerreroHFHelena Á. Ferrero
- Luis M. MateosLMLuis M. Mateos
- Álvaro MourenzaÁlvaro Mourenza
- Michal LetekMLMichal Letek
Open Access
- 19 March 2026
- journal article
- review article
- Published by MDPI AG in Antibiotics
- Vol. 15 (3) , 313
Abstract
Rhodococcus equi is an opportunistic intracellular pathogen responsible for severe pneumonia in foals and has emerged as an important cause of infection in immunocompromised humans. The treatment of R. equi infections in foals relies mainly on the combination of macrolides and rifampin. However, the increasing incidence of multidrug-resistant (MDR) isolates has raised significant therapeutic challenges. The mechanisms underlying this resistance include mutations in target genes, activation of efflux pumps, and biofilm formation, which collectively compromise the efficacy of conventional antibiotics. Recently, growing concern over antibiotic failure has accelerated research into alternative and synergistic strategies to enhance antibacterial efficacy and reduce the development of resistance. Natural and synthetic compounds, as well as optimized antibiotic combinations, have shown promising synergistic effects by enhancing intracellular accumulation, disrupting redox homeostasis, or inhibiting efflux systems. Experimental models employing checkerboard and time-kill assays, as well as redox-sensitive biosensors, have demonstrated that certain antibiotic combinations can influence bacterial susceptibility to antibiotic exposure. Furthermore, integrating molecular tools provides valuable insight into bacterial responses to oxidative and antibiotic stress, paving the way for novel therapeutic designs. This review summarizes the current understanding of the molecular factors contributing to antimicrobial resistance in R. equi and assesses new therapeutic approaches aimed at overcoming these challenges. It highlights recent findings on strategies to improve treatment outcomes and manage antimicrobial resistance.Keywords
This publication has 186 references indexed in Scilit:
- Dual drug delivery systems based on natural and synthetic polymer particles for isoniazid and rifampicin vehiculizationJournal of Applied Polymer Science, 2024
- Antimicrobial susceptibility of Rhodococcus equi strains isolated from foals in ChileWorld Journal of Microbiology and Biotechnology, 2023
- ROS‐Responsive Glycopolymeric Nanoparticles for Enhanced Drug Delivery to MacrophagesMacromolecular Bioscience, 2022
- Functionalization of PLGA Nanoparticles with 1,3-β-glucan Enhances the Intracellular Pharmacokinetics of Rifampicin in MacrophagesPharmaceutical Research, 2018
- Stimuli‐responsive liposomes for drug deliveryWIREs Nanomedicine and Nanobiotechnology, 2017
- The Rhodococcus equi virulence protein VapA disrupts endolysosome function and stimulates lysosome biogenesisMicrobiologyopen, 2016
- pH‐Responsive Isoniazid‐Loaded Nanoparticles Markedly Improve Tuberculosis Treatment in MiceSmall, 2015
- Prescottia equi gen. nov., comb. nov.: a new home for an old pathogenAntonie van Leeuwenhoek, 2012
- Effect of growth temperature on maintenance of virulent Rhodococcus equiVeterinary Microbiology, 1994
- Rhodococcus equi pneumonia in 48 foals: Response to antimicrobial therapyVeterinary Microbiology, 1987